nctId,briefTitle,phases,has_resultsSection,primary_outcomes_extracted,stats_or_conclusion_snippets,auto_suggest_outcome_label,auto_suggest_confidence,ctgov_url,error
NCT05888103,Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.,PHASE3,1.0,"Percentage Change in Low-density Lipoprotein Cholesterol (LDL-C) (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part | Baseline, Day 150 | Low-density lipoprotein cholesterol is a type of lipoprotein in the blood. Lipoproteins are particles made of lipids(fats) and proteins that carry fats t",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT05888103,
NCT04560998,A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes,PHASE3,1.0,"Change in Maximum Walking Distance on a Constant Load Treadmill Test | Baseline (week 0), end of treatment (week 52) | Change in maximum walking distance on a constant load treadmill test is presented. The constant-load treadmill test with fixed speed (3.2 km/h, 2 mph) and fixed inclination (12%) is",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT04560998,
NCT04471792,Creatine Use and Muscle Stretching in Peripheral Artery Disease,PHASE2,1.0,Walking Distance | Baseline and after 4 weeks of intervention | 6-minute walking test. This test measures the distance (in meters) that a patient can walk in 6 minutes.,e vs. post differences and creatine vs. placebo differences were examined ANOVA p=0.883 when comparing effect of creatine to palcebo on rate/change in reperfusion slop,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT04471792,
NCT04873934,Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome,PHASE3,1.0,Percent Change From Baseline to Day 330 in LDL-C | Baseline and Day 330 | Percent change from baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Day 330 || Achievement of LDL-C < 70 mg/dL at Day 330 | Day 330 | Percentage of participants achieving Low-Density Lipoprotein Cholesterol (LDL-C) \< 70 mg/dL at Day 330,,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT04873934,
NCT06005597,Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies,PHASE3,1.0,Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C | 84 Days | LS mean percent change in low-density lipoprotein cholesterol (LDL-C) from baseline to Day 84 in the obicetrapib 10 mg/ezetimibe 10 mg fixed-dose combination (FDC) group compared to the placebo group. LDL-C level was mea || Effect of Fixed Dose Combination (FDC) Compared to Ezetimibe Monotherapy on LDL-C | 84 Days | LS mean percent change in low-density lipoprotein cholesterol (LDL-C) from baseline to Day 84 in the obicetrapib 10 mg/ezetimibe 10 mg fixed-dose combination (FDC) group compared to the ezetimibe monotherap || Effect of Fixed Dose Combination (FDC) Compared to Obicetrapib Monotherapy on LDL-C | 84 Days | LS mean percent change in low-density lipoprotein cholesterol (LDL-C) from baseline to Day 84 in the obicetrapib 10 mg/ezetimibe 10 mg fixed-dose combination (FDC) group compared to the obicetrapib monoth || Effect of Obicetrapib Monotherapy Compared to Placebo on LDL-C | 84 Days | LS mean percent change in low-density lipoprotein cholesterol (LDL-C) from baseline to Day 84 in the obicetrapib 10 mg group compared to the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC).,,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT06005597,
NCT01064440,Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia,PHASE2,1.0,"Number of Participants With Treatment-emergent Adverse Events Following Intramuscular Administration of 8 and 16 mg Engensis (VM202) or Placebo in Subjects With Critical Limb Ischemia. | Baseline - Days 0, 14, 28, 42, 49, 90, 180, 270 and 365 | The number of participants with treatment-emergent adve || Change From Baseline in Visual Analog Scale (VAS) for Pain | Days 0, 90, 180, 270, and 365 | The Visual Analog Scale (VAS) for Pain scoring instrument is a 10 cm line, oriented horizontally, with the left end score of ""0"" indicating ""no pain"", and the right end score of ""10"" representing ""pain as ba",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT01064440,
NCT05142722,Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies,PHASE3,1.0,Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] | 84 Days | LS mean percent change from baseline to Day 84 in Low-Density Lipoprotein Cholesterol (LDL-C) in the obicetrapib group compared to the placebo group \[PUC\]. LDL-C level was measured by preparativ,,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT05142722,
NCT05761444,Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients,PHASE4,1.0,Percentage Change From Baseline in Low-Density Lipoprotein Cholesterol at Week 6 | Baseline (Day 1) and Week 6 | Blood samples were collected to determine the LDL-C values. The percentage change from baseline was defined as 100 x (LDL-C value at 6 weeks - LDL-C value at baseline)/LDL-C value at base,,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT05761444,
NCT02807779,Intima Versus Adventitia Drug Delivery to Elucidate Mechanisms of Restenosis: Magnetic Resonance Imaging,PHASE4,1.0,Change in Percent Wall Volume (PWV) | From Post-Operative Day One to 12 Months | The change in percent wall volume (PWV) of the treated segment between the postoperative and 12 month time points as measured by MRI,ing OTHER_PRE_SPECIFIED Fisher Exact Threshold for statistical significance was p=0.05. 0.81 SUPERIORITY OG002 OG001 OG000 1 OG002 4 OG001 4 OG000 1 OG002 9 OG001 10 ,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT02807779,
NCT05537571,Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events,PHASE2,1.0,Time-averaged Percent Change In Lipoprotein(a) Molar Concentration From Baseline to Week 36 | Week 36 | Clinical trial results (relative to Day 1 pre-dose) was calculated for each participant by estimating the sum of the area under the curve with the linear trapezoidal method for all scheduled asses,,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT05537571,
NCT04992065,A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease,PHASE2,1.0,"Percentage Change in Low-density Lipoprotein (LDL)-Cholesterol | Baseline (week 0), week 12 | Percentage change in LDL-cholesterol (LDL-C) (measured in milligrams per deciliter \[mg/dL\]) at week 12 is presented. Data is reported for the on-treatment period. The on-treatment period is the time perio",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT04992065,
NCT04929249,"A Randomized Study to Evaluate the Effect of an ""Inclisiran First"" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE)",PHASE3,1.0,"Percent Change From Baseline in LDL-C | Baseline, Day 330 | Percent change from baseline in Low-Density Lipoprotein Cholesterol (LDL-C) of an ""inclisiran first"" implementation strategy compared to usual care at Day 330. || Percentage of Participants Who Discontinued Statin Therapy | Day 330 | Percentage of patients who discontinued statin therapy ≥ 30 days before the end-of-study visit of an ""inclisiran first"" implementation strategy compared to usual care, for patients in the FAS excluding those with a medical histor",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT04929249,
NCT04270760,Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study,PHASE2,1.0,"Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36 | Baseline and Week 36 | Least squares mean is from the repeated measures linear effects model which includes treatment group, stratification factors, scheduled visit and the interaction of treatment group with scheduled visit.",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT04270760,
NCT02887859,Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PAD,PHASE2,1.0,"Number of Participants With Aneurysm Formation, Anastomotic Bleeding or Spontaneous Rupture, HAV Infection, HAV Removal, and Significant Inflammation at the HAV Implantation Site | 12 months || Number of Participants With Adverse Events | 12 months || Number of Participants With HAV Patency Rates (Primary, Primary-assisted, Secondary) | 12 months | Primary patency = patent (""open"" to blood flow) without any interventions; Primary-assisted patency = patent without an intervention to clear a thrombus; Secondary patency = patent with or without inte || Number of Participants With Hemodynamically Significant Stenosis (>70% by Duplex Ultrasound Criteria) | 12 months",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT02887859,
NCT05563246,A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events,PHASE2,1.0,"Percent Change From Baseline in Lp(a) - Assessed Via Intact Lp(a) Assay | Baseline, Week 12 | Least Squares Mean (LS Mean) was calculated using a Mixed Model for Repeated Measures (MMRM): Log (Actual Measurement/Baseline) = Log (Baseline) + Country + Treatment + Time + Treatment\*Time. || Percent Change From Baseline in Lp(a) - Assessed Via Apo(a) Assay | Baseline, Week 12 | LS Mean was calculated using a MMRM: Log (Actual Measurement/Baseline) = Log (Baseline) + Country + Treatment + Time + Treatment\*Time.",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT05563246,
NCT03018366,"Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women",PHASE2,1.0,"Rate of Change of Reactive Hyperemia Index (RHI) by Peripheral Arterial Tonometry | Baseline, week 12 on trial | Change in PAT measured as reactive hyperemia index (RHI) from baseline to week 12 on treatment or placebo. Reactive hyperemia index (RHI) is the post-to-pre occlusion PAT signal ratio in ",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT03018366,
NCT04881110,Liraglutide and Peripheral Artery Disease,PHASE4,1.0,Peripheral Transcutaneous Oxygen Pressure | 6 months | Transcutaneous oxygen pressure (mmHg) on the lowest value recorded on anterior or posterior tibial artery after 6 months, reached the primary end point after the intervention. Relative risks (RRs) and 95%Cis were calculated to demonstrate the relationship between the intervention and t,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT04881110,
NCT04610892,Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction,PHASE2,1.0,"Change From Baseline to Day 253 in Non-calcified Plaque Volume in the Most Diseased Coronary Segment (NCPVMD), as Measured by Computed Tomography Angiography (CTA) Imaging | From baseline to Day 253 | To evaluate the effect of MEDI6570 on non-calcified coronary atherosclerotic plaques compared with ",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT04610892,
NCT03473223,Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome,PHASE3,1.0,"Number of Participants With First Occurrence of Any Component of Composite MACE (CV Death, MI, or Stroke) | From the time of randomization through 90 days | MACE (Major adverse cardiovascular event\[s\])(CV \[cardiovascular\] death, MI \[Myocardial Infarction\], or stroke).",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT03473223,
NCT03743636,Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease,PHASE3,1.0,"Six-minute Walk Distance (NR Alone vs. Placebo) | Baseline to 6-month follow-up | Among participants with PAD, investigators will determine whether NR alone improves six-minute walk distance at 6-month follow-up, compared to placebo. || Six-minute Walk Distance (NR/Resveratrol vs. Placebo) | Baseline to 6-month follow-up | Among participants with PAD, investigators will determine whether NR combined with resveratrol improves six-minute walk performance at 6-month follow-up, compared to placebo.",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT03743636,
NCT05421078,A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.,PHASE2,1.0,Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald] | 8 Weeks | Mean percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C was calculated using the Friedewald equation unless TG≥4 || Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald] | 8 Weeks | Median percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C was calculated using the Friedewald equation unless  || LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald] | 8 Weeks | LS Mean percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C was calculated using the Friedewald equation unles || Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC] | 8 Weeks | Mean Percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC). || Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC] | 8 Weeks | Median Percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC),,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT05421078,
NCT03064126,RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty,PHASE3,1.0,"Number of Participants With Primary Lesion Patency | 12 months (RCT); 6 months (LB substudy) | RCT outcome measure: Primary patency of the target lesion is determined by Peak Systolic Velocity Ratio (PSVR) ≤ 2.4 (by duplex ultrasound (DUS)) and freedom from clinically-driven Target Lesion Revascular || Major Adverse Events (MAEs) (Primary Safety Endpoint) | Primary safety endpoint assessed at 12 months for RCT study and at both 6 and 12 months for LB substudy. | RCT: MAE is defined as a composite of freedom from all-cause death through 1 month, target limb major amputation (defined as at or above ",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT03064126,
NCT02376010,Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium,PHASE4,1.0,Coronary Artery Calcium (Serial Calcium Scans) | 1 year | serial calcium scans,,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT02376010,
NCT04807400,Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support,PHASE3,1.0,"Percentage Change in LDL-C From Baseline to Day 270 | Baseline, Day 270 | Change in Low Density Lipoprotein Cholesterol (LDL-C) after 270 days of treatment in adults on established lipid lowering medication or who have been recommended lipid lowering therapy by their health care provider but are una",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT04807400,
NCT03689946,Effect of Evolocumab on Coronary Atherosclerosis,PHASE3,1.0,Change in Noncalcified Coronary Artery Plaque Volume (NCPV) | baseline (pre-treatment) and 18 months after of treatment | Compare NCPV in mm\^3 measured on cardiac CT images as analyzed by quantitative software between the two assessments,,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT03689946,
NCT04753606,Randomized Study of Obicetrapib as an Adjunct to Statin Therapy,PHASE2,1.0,"Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald] | 8-weeks | Mean percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group.LDL-C was calculated using the Friedewald equation unless TG

≥ || Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald] | 8-Weeks | Median Percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. \[Friedewald\] LDL-C was calculated using the Friedewald e || LS Mean Percent Change Iin Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald] | 8-Weeks | LS mean percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. \[Friedewald\] LDL-C was calculated using the Friedewal || Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC] | 8-Weeks | Mean Percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC). || Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [PUC] | 8-Weeks | Median Percent change from Day 1 to Day 56 in Low-Density Lipoprotein Cholesterol (LDL-C) for each obicetrapib group compared to the placebo group. LDL-C level was measured by preparative ultracentrifugation (PUC)",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT04753606,
NCT05266586,Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy,PHASE2,1.0,Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [Friedewald] | 12-weeks | Mean percent change from Day 1 to Day 84 in Low-Density Lipoprotein Cholesterol (LDL-C) for the obicetrapib 10 mg + ezetimibe 10 mg combination || Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [Friedewald] | 12-Weeks | Median percent change from Day 1 to Day 84 in Low-Density Lipoprotein Cholesterol (LDL-C) for the obicetrapib 10 mg + ezetimibe 10 mg combina || LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [Friedewald] | 12-Weeks | LS Mean percent change from Day 1 to Day 84 in Low-Density Lipoprotein Cholesterol (LDL-C) for the obicetrapib 10 mg + ezetimibe 10 mg combi || Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [PUC] | 12-Weeks | Mean percent change from Day 1 to Day 84 in Low-Density Lipoprotein Cholesterol (LDL-C) for the obicetrapib 10 mg + ezetimibe 10 mg combination treatm || Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [PUC] | 12-Weeks | Median percent change from Day 1 to Day 84 in Low-Density Lipoprotein Cholesterol (LDL-C) for the obicetrapib 10 mg + ezetimibe 10 mg combination tr,,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT05266586,
NCT03551496,The DES BTK Vascular Stent System vs PTA in Subjects With Critical Limb Ischemia,PHASE3,1.0,"Number of Participants With Primary Patency | 12 months | Twelve-Month Primary Patency defined as a binary endpoint to be determined via duplex ultrasound (DUS) measuring flow at the 12-month follow-up visit, in the absence of clinically-driven target lesion revascularization (TLR) or bypass of the  || Number of Participants Free From Major Adverse Events (MAE) | 12 months | The primary safety endpoint assesses freedom from major adverse events (MAE) at 12 months post-procedure. (MAE is defined as: above ankle amputation in index limb; major re-intervention; and perioperative (30 day) mortality)",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT03551496,
NCT03363165,Hepatocyte Growth Factor to Improve Functioning in PAD,PHASE2,1.0,Six-minute Walk Distance | Change from baseline to six-month follow-up in six-minute walk distance | Participants walking up and down a 100 foot hallway for six minutes following a standardized protocol. The goal is for them to walk as far as possible in six minutes,,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT03363165,
NCT00496834,LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED),PHASE4,1.0,Pulse Wave Velocity (PWV) Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug | Baseline and 24 Weeks | Analysis was performed in the modified intention to treat (mITT) population. || PWV Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug | Baseline and 24 Weeks | Analysis was performed in the per protocol (PP) population which additionally excludes certain protocol violations as described in the analysis plan.,,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT00496834,
NCT05742841,EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders),PHASE4,1.0,Low-density Lipoprotein Cholesterol (LDL-C) Levels at Baseline and Day 30 | Baseline and Day 30 | A lipid panel is a common blood test that healthcare providers use to monitor and screen for risk of cardiovascular disease. The panel includes three measurements of your cholesterol levels and a measur,,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT05742841,
NCT04770389,Randomized Study of Obicetrapib in Combination With Ezetimibe,PHASE2,1.0,Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [Friedewald] | 8 weeks | Mean percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula || Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [Friedewald] | 8 weeks | Median percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula || LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [Friedewald] | 8 weeks | LS Mean percent change in LDL-C from baseline to Day 57; LDL-C determined using the Friedewald formula || Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [PUC] | 8 weeks | Mean percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC) || Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [PUC] | 8 weeks | Median percent change in LDL-C from baseline to Day 57; LDL-C measured using preparative ultracentrifugation (PUC),,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT04770389,
NCT03329599,Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment,PHASE2,1.0,Carotid Intimal Media Thickness | Baseline and 12 months | Thickness of the intima and media layers of the carotid arteries,,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT03329599,
NCT02169089,Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Trial,PHASE4,1.0,Percent Change in Atheroma Volume (PAV) in the Thoracic Aorta of Spironolactone vs. Placebo | 56 weeks,,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT02169089,
NCT02431325,A Study of the Gut Barrier and Blood Vessel Inflammation in Individuals With and Without HIV,PHASE2,1.0,"Change in Arterial Target to Background Ratio of 18-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Uptake | Change from baseline at 6 months | Change in maximum target to background ratio (TBRmax) of the most diseased segment (MDS) of the carotid index vessel. A negative number for the ch || Change in Intestinal Epithelial Integrity | Change from baseline at 6 months | Change in plasma citrulline is calculated as log2 of the ratio of plasma citrulline at study end to baseline. Citrulline is a measure of functional small bowel mass, so a positive number is considered an improvement in in || Change in Soluble CD14 Concentration | Change from baseline at 6 months | Soluble CD14 is a marker of monocyte activation. An increase in soluble CD14 concentration indicates an increase in inflammation.",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT02431325,
NCT00118846,,,,,,,,,"HTTPSConnectionPool(host='clinicaltrials.gov', port=443): Max retries exceeded with url: /api/v2/studies/NCT00118846?format=json (Caused by SSLError(SSLEOFError(8, '[SSL: UNEXPECTED_EOF_WHILE_READING] EOF occurred in violation of protocol (_ssl.c:1000)')))"
NCT03060577,An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol,PHASE2,1.0,Percentage Change in LDL-C From Baseline of the ORION-1 Study to Day 210 in ORION-3 (Inclisiran Arm) | Baseline (ORION-1) and Day 210 (ORION-3) (up to 570 days total) | Percent Change in LDL-C (beta-quantification) from baseline of the ORION-1 Study to Day 210 in ORION-3. A negative percentage score,,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT03060577,
NCT03829046,The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular Disease,PHASE4,1.0,"Number of Adverse Events | up to 12 weeks | Safety as measured by number of adverse events, defined as any untoward medical occurrence in a subject who has been administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT03829046,
NCT02926027,Effect of Vascepa on Improving Coronary Atherosclerosis in People With High Triglycerides Taking Statin Therapy,PHASE4,1.0,Progression Rates of Low Attenuation Plaque Under Influence of Vascepa as Compared to Placebo as a Change Between Two or More Time Points | 18 months | low attenuation plaque volume change from baseline to 18 months,,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT02926027,
NCT00114517,ELITE: Early Versus Late Intervention Trial With Estradiol,PHASE2,1.0,Progression of Subclinical Atherosclerosis | Baseline x 2 and then every 6 months up to 6.7 years | Rate of change in distal common carotid artery (CCA) far wall intima-media thickness (mm per year) in computer image processed B-mode ultrasonograms that were obtained at two baseline examinations (av,,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT00114517,
NCT01776424,Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease,PHASE3,1.0,"The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death | For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (0 || The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria | For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspiri",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT01776424,
NCT03364270,TRACER [F-18] RDG-K5 Carotid Plaque Imaging Study,PHASE2,1.0,Uptake of [F-18] RGD-K5 by Carotid Plaque With PET/MRI Imaging in the Artery Believed to be the Cause of Transient Ischemic Attack (TIA) or Stroke Symptoms Compared to the Contralateral Carotid Artery Not Implicated in TIA or Stroke | within 96 hrs of a stroke or TIA (transient ischemic attack) | To,,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT03364270,
NCT01121224,Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty,PHASE4,1.0,"Number of Participants With Target Vessel Failure (TVF), Defined as the Composite of Cardiac Death | 12 months || Number of Participants With Target Vessel Failure (TVF), Defined as the Target Vessel Myocardial Infarction | 12 months || Number of Participants With Target Vessel Failure (TVF), Defined as the Target Vessel Revascularization | 12 months",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT01121224,
NCT03718429,Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies,PHASE4,1.0,"Platelet-Mediated Global Thrombogenicity | 20 days | Comparison of platelet-mediated global thrombogenicity measured by light transmittance aggregometry following collagen-related peptide+adenosine diphosphate+ tissue factor (CATF) stimuli between aspirin plus clopidogrel vs. aspirin plus clopidogre || Platelet Aggregation Measured by VerifyNow PRU | 20 days | P2Y12 reaction units (PRU) by VerifyNow of dual antiplatelet therapy vs. dual antiplatelet therapy plus rivaroxaban. VerifyNow is a turbidimetric based optical detection system which measures platelet aggregation induced by ADP as an increas || Thrombin Generation | 20 days | Comparison of thrombin generation, reported as peak thrombin level measured by a thrombin generation assay, between aspirin plus clopidogrel vs. aspirin plus clopidogrel plus rivaroxaban. This is reflective of the amount of thrombin that is generated following stimuli",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT03718429,
NCT00715273,Evaluate Carotid Artery Plaque Composition by Magnetic Resonance Imaging in People Receiving Cholesterol Medication,PHASE4,1.0,"Annualized LRNC Volume Change in Carotid Plaque Composition, as Assessed by MRI | Measured at Years 1, 2, and 3 | The primary endpoint of this study is carotid plaque lipid composition identified by MRI. The determination of plaque lipid content for each carotid artery will be performed using the au || Annualized LRNC and Wall Volume Changes in Carotid Plaque Composition, as Assessed by MRI | Measured at Years 1, 2, and 3 | The primary endpoint of this study is carotid plaque lipid composition identified by MRI. The determination of plaque lipid content for each carotid artery will be performed us",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT00715273,
NCT00455325,Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS),PHASE2,1.0,Insulin Sensitivity | assessed every 8 - 10 weeks at the end of each treatment period | Hepatic insulin sensitivity was measured by comparing glucose production at baseline of zero insulin infusion rate with glucose production at 56 pmol/m2/min. Hepatic insulin sensitivity was expressed as the perce,,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT00455325,
NCT02325466,Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes,PHASE3,1.0,"Mean Change in Low Shear Blood Viscosity | baseline, week 16 | Compare the effect of aspirin-ticagrelor and ticagrelor monotherapy with aspirin on blood viscosity from week 16 to baseline || Mean Change in High Shear Blood Viscosity | baseline and week 16 | Compare the effect of aspirin-ticagrelor and ticagrelor monotherapy with aspirin on blood viscosity at week 16 to baseline",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT02325466,
NCT03011775,"Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease",PHASE4,1.0,"Сardiovascular Death | Baseline and 1 year | Number of Participants with cardiovascular death || Coronary Artery Bypass [Coronary Revascularization] | Baseline and 1 year | Number of Participants with revascularization coronary procedures (coronary artery bypass grafting) || Cardiovascular Hospitalization | Baseline and 1 year | Number of Participants with acute coronary syndrome (ACS) or unstable angina (UA) || Percutaneous Coronary Intervention [Coronary Revascularization] | Baseline and 1 year | Number of Participants with incidence of percutaneous coronary intervention. || Safety and Tolerability 1 | Baseline, 6 month and 1 year | Liver injury: mean values of ALT",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT03011775,
NCT03096288,Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity,PHASE4,1.0,Platelet Reactivity Defined by VerifyNow PRU in HPR and NPR Patients | 30 days | The primary end point of our study is the comparison of P2Y12 reaction units (PRU) measured by VerifyNow between evolocumab and placebo at 30 days after randomization. PRU is a well-established measure of platelet react,,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT03096288,
NCT00189540,Study of Hepatocyte Growth Factor (HGF) Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Patients With Peripheral Ischemic Ulcers,PHASE2,1.0,"Wound Healing (Change in Total Wound Area of All Ischemic Ulcers) | Baseline, Month 3, Month 6 | Wound healing measured by change in mean total wound area of all ischemic ulcers at Month 3 and Month 6",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT00189540,
NCT02624180,Inflammatory Pathogenesis of Coronary Atherosclerosis in HIV,PHASE2,1.0,Coronary Endothelial Function Measured by Percent Change in Coronary Blood Flow With Exercise (%) at 8 Weeks | Difference between measurements at baseline compared to measurement at 8 weeks | Percent change in coronary blood flow (CBF) from rest to that during isometric handgrip exercise (IHE) stres,,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT02624180,
NCT03228017,Subclinical Cardiovascular Disease in Psoriatic Disease,PHASE4,1.0,"Mean Fold Change in Brachial Vein Endothelial Inflammatory Transcript | Baseline, 5 Months | Endothelial sampling coupled to real-time PCR analysis will be used to monitor brachial vein endothelial inflammation",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT03228017,
NCT02338999,Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE),"PHASE1,PHASE2",1.0,"Change in Vascular Function and Cardiometabolic Risk as Measured by Left CAVI at Month 3 | 3 months after start of first intervention (Baseline to 3 months) | Change in vascular function using non-invasive vascular tests, measuring vascular compliance - Cardio ankle vascular index (CAVI).

CAVI is a || Change in Vascular Function and Cardiometabolic Risk as Measured by Left CAVI at Month 8 | 3 months after start of second intervention (5 months to 8 months) | Change in vascular function using non-invasive vascular tests, measuring vascular compliance - Cardio ankle vascular index (CAVI).

CAVI is  || Change in Vascular Function and Cardiometabolic Risk as Measured by Right CAVI at Month 3 | 3 months after start of first intervention (Baseline to 3 months) | Change in vascular function using non-invasive vascular tests, measuring vascular compliance - Cardio ankle vascular index (CAVI).

CAVI is  || Change in Vascular Function and Cardiometabolic Risk as Measured by Right CAVI at Month 8 | 3 months after start of second intervention (5 months to 8 months) | Change in vascular function using non-invasive vascular tests, measuring vascular compliance - Cardio ankle vascular index (CAVI).

CAVI is || Change in Vascular Function and Cardiometabolic Risk as Measured by PWV at Month 3 | 3 months after start of first intervention (Baseline to 3 months) | Change in vascular function using non-invasive vascular tests, measuring vascular compliance -Pulse, wave, velocity (PWV).

The central aortic pres",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT02338999,
NCT03485495,Clinical Trial of Efficacy and Safety of Divaza for Adjustment of Oxidative Disorders in Patients With Cerebral Atherosclerosis,PHASE4,1.0,Change in Mean Value of Lipoprotein Resistance to LPO. | 12 weeks of the observation period. | Based on laboratory evaluation. Change in the mean resistance of lipoprotein (LP) to lipid peroxidation (LPO) after 12-week therapy versus baseline.,,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT03485495,
NCT02104817,Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia,PHASE3,1.0,"The Composite of Major Adverse Cardiovascular Events (MACE) | From the date of randomization and up to completion of the end-of-treatment visit (Month 60) or at study closure | MACE components include: cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, emergent/elective",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT02104817,
NCT00147251,Stop Atherosclerosis in Native Diabetics Study,PHASE4,1.0,"Changing LDL Cholesterol | 36 months | LDL cholesterol intervention to lower targets than are currently recommended to retard atherosclerosis measured by LDL-C mg/dL.

Scale: LDL cholesterol levels should be less than 100 mg/dL",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT00147251,
NCT01099215,Study of PVS-10200 for the Treatment of Restenosis in Patients With Peripheral Artery Disease (TRIUMPH),"PHASE1,PHASE2",1.0,Incidence of Major Adverse Events (MAEs) | within 4 weeks after study procedure | Major Adverse Events are: - Death - Major amputation - Procedural related serious adverse events - Investigational product related serious adverse events,,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT01099215,
NCT00228423,Trial of Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial),PHASE2,1.0,"Vein Graft Intimal Area | One year following surgery | IVUS imaging 12 months post-CABG, and the average intimal area in the proximal 40 mm of one vein graft per patient will be assessed",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT00228423,
NCT03067441,Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE),PHASE3,1.0,Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Up to Week 82 | TEAEs are defined as adverse events that began or worsened in severity after the first dose of investigational medicinal product (IMP) until 30 days after the last dose in the Open-Label Extension (OLE) Study.,,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT03067441,
NCT02217501,Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities,PHASE3,1.0,"Number of Participants With First Occurrence of Target Vessel Occlusion, Surgical Revascularization, Endovascular Revascularization, Major Amputation of Target Limb, Ischemic Stroke, MI, or Death | 12 months from index procedure or end of study treatment, whichever is longer, assessed up to 2 years ",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT02217501,
NCT01645306,Revacept in Symptomatic Carotid Stenosis,PHASE2,1.0,New DWI Lesion(s) | 1 day post intervention | The number of new diffusion weighted imaging (DWI) lesion(s) reported. (1 day after intervention compared to baseline).,,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT01645306,
NCT02016755,A Phase IIB Pilot Study of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia,PHASE2,1.0,"Number of Participants With Adverse Events (AEs) Suspected to be Related to Injections of AMG0001 | 18 months | All summaries and analyses will be presented in tabular or graphical form. The study is not powered for the statistical inference and the test will be considered to be descriptive.

Treatm || Number of Participants Discontinued Due to AEs From the Injections of AMG0001 | up to 18 Months | All summaries and analyses will be presented in tabular or graphical form. The study is not powered for the statistical inference and the test will be considered to be descriptive.

Treatment-emergent a",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT02016755,
NCT00403494,A Phase 2 Study of the Effects of Sapropterin Dihydrochloride on Symptomatic Peripheral Arterial Disease,PHASE2,1.0,"Change in Peak Walking Time (PWT) From Baseline | Baseline and up to Week 24 | This is to assess the effect of oral sapropterin dihydrochloride versus placebo on peak walking time (PWT) in subjects with intermittent claudication (IC) caused by peripheral arterial disease (PAD). || Number of Subjects With Adverse Events (AEs) | Up to 24-weeks | Adverse events were described and summarized with focus on treatment- emergent events (TEAEs). A TEAE was defined as any AE that presented , increased in frequency or worsened in severity following initiation of study drug administratio",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT00403494,
NCT03194776,Study of LLG783 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication,PHASE2,1.0,"Number of Participants With Adverse Events (AEs), Drug-related AEs, Serious Adverse Events (SAEs) and Deaths | Up to 32 Weeks | An AE is any untoward medical occurrence (that is, any unfavorable and unintended sign, including abnormal laboratory findings, symptom or disease) in a participant after p || Change From Baseline in Maximum Walking Distance (MWD) as Assessed by 6-minute Walk Test (6MWT) at Week 16 | Baseline, Week 16 (Day 113) | MWD was assessed by the 6MWT prior to dosing was used to evaluate functional capacity of peripheral artery disease (PAD) participants. 6MWT test included measure",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT03194776,
NCT02504216,Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities,PHASE3,1.0,"Primary Efficacy Outcome: Number of Participants With Composite of Myocardial Infarction (MI), Ischemic Stroke, Cardiovascular Death, Acute Limb Ischemia (ALI) and Major Amputation Due to a Vascular Etiology | For each participant, the first occurrence of the composite primary efficacy outcome after || Primary Safety Outcome: Number of Participants With TIMI (Thrombolysis in Myocardial Infarction) Major Bleeding | For each participant, the first occurrence of the primary safety outcome after randomization up until 2 days after permanent stop of study drug (rivaroxaban or rivaroxaban placebo). | On",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT02504216,
NCT03469349,Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB,PHASE3,1.0,Percent Change From Baseline in Initial Claudication Distance (ICD) at Week 12 | Baseline up to Week 12 | ICD was the distance walked at the onset of claudication pain or pain-free walking distance. ICD was assessed using treadmill testing. A fixed load treadmill test was carried out at 3.0 kilomete,,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT03469349,
NCT03399370,Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol,PHASE3,1.0,"Percentage Change in LDL-C From Baseline to Day 510 | Baseline, Day 510 || Time-adjusted Percentage Change in LDL-C Levels From Baseline After Day 90 and up to Day 540 | Baseline, Day 90 to Day 540 | Assessments performed at Baseline, Day 90, Day 540, time-adjusted percent change at Day 540 reported",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT03399370,
NCT01813357,Does Rosuvastatin Delay Progression of Atherosclerosis in HIV,PHASE4,1.0,Progression of Carotid Intima Media Thickness | Baseline to week 96 | Carotid intima media thickness will be measured by ultrasonography and the change from baseline to week 96 calculated,,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT01813357,
NCT03400800,Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol,PHASE3,1.0,"Percentage Change in LDL-C From Baseline to Day 510 | Baseline, Day 510 || Time-adjusted Percent Change in LDL-C Levels From Baseline After Day 90 and up to Day 540 | Baseline, Day 90 to Day 540",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT03400800,
NCT02666664,Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony),PHASE3,1.0,"Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | Up to approximately 52 weeks | TEAEs, defined as adverse events (AEs) that began or worsened in severity after the first dose of double-blind study drug and up to 30 days after receiving the last dose of double-blind study d || Percentage of Participants With Adjudicated Major Adverse Cardiovascular Event | Up to approximately 52 weeks | TEAEs, defined as AEs that began or worsened in severity after the first dose of double-blind study drug and up to 30 days after receiving the last dose of double-blind study drug, were co || Percentage of Participants With the Indicated Event of Special Interest: Creatine Kinase Elevations | Up to approximately 52 weeks | TEAEs of special interest (AESIs) were predefined and monitored throughout the study. Creatine kinase elevations were assessed using the following preferred term: Bloo || Percentage of Participants With the Indicated Event of Special Interest: Hepatic Disorders | Up to approximately 52 weeks | Treatment-emergent AESIs were predefined and monitored throughout the study. TEAEs potentially related to hepatic events were assessed using the following preferred terms and l || Percentage of Participants With the Indicated Event of Special Interest: Hypoglycemia | Up to approximately 52 weeks | Treatment-emergent AESIs were predefined and monitored throughout the study. Hypoglycemia was assessed using the following preferred terms: hypoglycaemia (system organ class: metabo",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT02666664,
NCT03001076,Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility),PHASE3,1.0,Percent Change From Baseline to Week 12 in Low-Density Lipoprotein Cholesterol (LDL-C) | Week 12 | Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for LDL-C. Baseline was defined as the mean of the LDL-C values,,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT03001076,
NCT02991118,Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk,PHASE3,1.0,Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C) | Baseline; Week 12 | Baseline is defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Percent change from Baseline is calculated as (\[post-baseline value minus basel,,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT02991118,
NCT01401517,"Phase IIa: Safety, PK, & Tolerability of Sodium Nitrite in Patients With Peripheral Arterial Disease-SONIC",PHASE2,1.0,Reporting of Adverse Events During 11 Week Treatment Period. | 11 weeks | The primary objective of this clinical study is to evaluate the safety and tolerability of multiple doses of twice daily 40mg and 80mg sodium nitrite compared with placebo over a 10 week treatment period. Subjects will be aske,,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT01401517,
NCT02576067,Cardiovascular Inflammation Reduction Trial - Inflammation Imaging Study,PHASE3,1.0,Change in Arterial Inflammation | baseline and 8 months | Change in arterial inflammation - The relative change at 8 months as compared to baseline in arterial inflammation as measured by the most diseased segment (MDS) of the index vessel. The MDS is defined as the 1.5 cm segment within the carotid,,NEGATIVE,LOW/MED (auto),https://clinicaltrials.gov/study/NCT02576067,
NCT03337308,"A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy",PHASE3,1.0,Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C) | Baseline; Week 12 | Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for LDL-C. Baseline was defined as the mean of the LD,,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT03337308,
NCT02988115,Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant,PHASE3,1.0,Percent Change From Baseline (PCFB) in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12 | Baseline; Week 12 | PCFB was calculated as the (\[post-Baseline (BL) value minus the BL value\] divided by the BL value ) x 100. BL was defined as the mean of the last two non-missing values on or prior t,,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT02988115,
NCT03358355,Unacylated Ghrelin to Improve FuncTioning in PAD: The GIFT Trial,"PHASE1,PHASE2",1.0,Levels of Unacylated Ghrelin | Baseline and at scheduled intervals up to 24 hours after baseline | Levels of unacylated ghrelin are measured before and after every injection,,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT03358355,
NCT02819011,"OHI--Randomized Control Trial to Evaluate Efficacy, Acceptability, and Perception of Benefit of an Innovative Custom AFO",PHASE2,1.0,Hip Sway Change From Baseline to 6 Months | baseline to 6 months | Hip sway (motion of hip joints in three dimensions) measured by wearable sensors while wearing their own shoes compared to the orthopedic shoes and compared to orthopedic shoes plus Ankle-Foot Orthosis (AFO) || Ankle Sway Change From Baseline to 6 Months | baseline to 6 months | Ankle sway (motion of ankle joint in three dimensions) measured by wearable inertial sensors while wearing their own shoes compared to the orthopedic shoes and compared to orthopedic shoes plus Ankle-Foot Orthosis (AFO) || Center of Mass (COM) Sway Change Baseline to 6 Months | baseline to 6 months | Center of Mass (COM) sway measured by wearable inertial sensors while wearing their own shoes compared to the orthopedic shoes and compared to orthopedic shoes plus Ankle-Foot Orthosis (AFO),,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT02819011,
NCT02548650,Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus,PHASE4,1.0,Maximal Platelet Aggregation in DM | 30 days | Comparison of maximal platelet aggregation (%) measured by light transmittance aggregometry between between triple (vorapaxar plus DAPT) and dual (vorapaxar plus clopidogrel) therapy in diabetic patients,,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT02548650,
NCT00687076,Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study),PHASE4,1.0,Effect of Intensive Lipid Modification Medication Therapy on Progression of Atherosclerosis and Restenosis of Femoral Arteries Measured Using High Resolution Magnetic Resonance Imaging (MRI) to Examine the Femoral Artery for Progression of Atherosclerosis | Measured at baseline and 24 Months | The p,,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT00687076,
NCT01327846,Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events),PHASE3,1.0,"Analysis of Core Phase First CEC Confirmed Major Adverse Cardiovascular Events (MACE) and Its Components | From randomization, to end of treatment plus 30 days, up to approximately 6 years | Time to occurrence of CEC (Cardiovascular clinical events adjudication committee) confirmed MACE, which was a || Substudy 1 (Core Phase): Change From Baseline in Carotid Plaque Burden in the Bifurcation Region of the Index Carotid Artery | 24 months || Substudy 2 (Core Phase): Change From Baseline of the Insulin Secretion Rate (ISR) Relative to Glucose 0-30 Min Defined as Φ30 = AUCISR 0-30 / AUCGluc 0-30 Averaged Across the Year 3, 4, 5 Visits | From randomization up to approximately 6 years",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT01327846,
NCT00330733,Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk,"PHASE2,PHASE3",1.0,Change in Systemic Glucose Disposal- Glucose Infusion Rates | 3 months | Participants were admitted to the Clinical Research Units at 06:00-08:00 hours after an overnight fast. Euglycaemic-hyperinsulinaemic clamps were conducted at baseline and at the end of the study. Because salsalate therapy appe,,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT00330733,
NCT02546323,A phase3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects With Subclinical Atherosclerosis,PHASE3,1.0,Annualized Rate of Change in Mean of the Maximum (MeanMax) CIMT Measurements From Each of the 12 Carotid Artery Sites Based on All Scans Performed During the 104-Week Study Period | From baseline (pre-randomization Week -2 and Week -4) to end-of-study (Week 104). | CIMT measurements were made from u,,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT02546323,
NCT02260622,,,,,,,,,"HTTPSConnectionPool(host='clinicaltrials.gov', port=443): Max retries exceeded with url: /api/v2/studies/NCT02260622?format=json (Caused by SSLError(SSLEOFError(8, '[SSL: UNEXPECTED_EOF_WHILE_READING] EOF occurred in violation of protocol (_ssl.c:1000)')))"
NCT00822172,Evaluation of Cilostazol in Combination With L-Carnitine,PHASE4,1.0,"Change From Baseline in Peak Walking Time (PWT) at Day 180 | Baseline, Day 180 | Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their pe",,UNCLEAR,LOW (auto),https://clinicaltrials.gov/study/NCT00822172,
